AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22947235 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 30
Study 22947235 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 30
Study 22947235 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% and 0.25% bupivacaine
Number of subjects: 30
Study 21884542 — intervention group
Group type: EXPERIMENTAL
Intervention: Strongly identified young adults
Number of subjects: 0
Study 21884542 — intervention group
Group type: EXPERIMENTAL
Intervention: Expecting to identify with future aged in-group
Number of subjects: 0
Study 21884542 — intervention group
Group type: EXPERIMENTAL
Intervention: Membership in future in-group being highly salient
Number of subjects: 0
Study 21884542 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' written descriptions of old age and valence manipulation
Number of subjects: 0
Study 19335503 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home preparation group (experimental group)
Number of subjects: 158
Study 19335503 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control group)
Number of subjects: 158
Study 17269982 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% silver nitrate solution
Number of subjects: 60
Study 17269982 — intervention group
Group type: COMPARATOR
Intervention: Black ink (placebo)
Number of subjects: 60
Study 15516638 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (14 days of ferrous sulfate and an antimalarial)
Number of subjects: 209
Study 15516638 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended treatment (three months of ferrous sulfate and three antimalarial treatments)
Number of subjects: 209
Study 11699685 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving welfare
Number of subjects: 833
Study 11699685 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaving welfare by child's third birthday
Number of subjects: 833
Study 9446377 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon interposition with anastomosis to gastric fundus
Number of subjects: 113
Study 9446377 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoperistaltic grafts
Number of subjects: 113
Study 9446377 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiperistaltic grafts
Number of subjects: 113
Study 9446377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 113
Study 8182625 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac coadministered with MTX (10 mg)
Number of subjects: 19
Study 8182625 — intervention group
Group type: COMPARATOR
Intervention: MTX (10 mg) without etodolac
Number of subjects: 19
Study 30196174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: KWs affixed to surgical towels
Number of subjects: 16
Study 30196174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Screws with metal extensors
Number of subjects: 16
Study 30196174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Screws with plastic extensors (K2M)
Number of subjects: 16
Study 30196174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: Screws without extensors or tulips (Nuvasive)
Number of subjects: 16
Study 30196174 — intervention group
Group type: EXPERIMENTAL
Intervention: Precept Modular (Nuvasive)
Number of subjects: 16
Study 27650977 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 736
Study 27650977 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 736
Study 25638698 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 60
Study 25638698 — intervention group
Group type: EXPERIMENTAL
Intervention: CTI ablation
Number of subjects: 60
Study 25638698 — intervention group
Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (PVI)
Number of subjects: 60
Study 23622565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics + oral steroids (Group 2)
Number of subjects: 21
Study 23622565 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics (Group 1)
Number of subjects: 21
Study 21183919 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptol (32 patients)
Number of subjects: 189
Study 21183919 — intervention group
Group type: COMPARATOR
Intervention: Pantoham (30 patients)
Number of subjects: 189
Study 18467719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,250 mg daily
Number of subjects: 416
Study 18467719 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT)
Number of subjects: 416
Study 18467719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,250 mg daily (in patients with EGFR-overexpressed tumors)
Number of subjects: 416
Study 18467719 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT) (in patients with EGFR-overexpressed tumors)
Number of subjects: 416
Study 16331117 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg
Number of subjects: 135
Study 16331117 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 135
Study 12583871 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone (5HT1A receptor agonist)
Number of subjects: 40
Study 10885420 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training on a treadmill, 4 days/week (group S; n=21)
Number of subjects: 35
Study 10885420 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitored walking 3 or 4 km in 1 h, 4 days/week (group SM; n=20)
Number of subjects: 35
Study 8772550 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg orally at -270 min and 250 mg orally at -60 min)
Number of subjects: 31
Study 8772550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg orally at -60 min) with Acipimox
Number of subjects: 31
Study 8772550 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms iv at 0 min) with Acipimox
Number of subjects: 31
Study 8772550 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH plus GHRP-6 (100 micrograms iv at 0 min) with Acipimox
Number of subjects: 31
Study 8772550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered at similar intervals as Acipimox)
Number of subjects: 31
Study 1602106 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% (Voltaren)
Number of subjects: 0
Study 1602106 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 1% (Indocid)
Number of subjects: 0
Study 1602106 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 4091874 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg capsules, daily dosage limited to 400 mg for 3 weeks)
Number of subjects: 153
Study 4091874 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (1.6 mg i.m.)
Number of subjects: 153
Study 4091874 — intervention group
Group type: COMPARATOR
Intervention: Saline (i.m.)
Number of subjects: 153
Study 29571962 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-free TPE
Number of subjects: 164
Study 29571962 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin TPE
Number of subjects: 164
Study 26295176 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual nutritional counseling for seven sessions (baseline, weeks 2, 4, 8, 12, 18, and 24)
Number of subjects: 72
Study 26295176 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal diet information at baseline and nutritional counseling only at week 24
Number of subjects: 72
Study 24772412 — intervention group
Group type: COMPARATOR
Intervention: 3 mL 0.5% levobupivacaine solution at room temperature (Group I)
Number of subjects: 0
Study 24772412 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL 0.5% levobupivacaine solution at 37 °C (Group II)
Number of subjects: 0
Study 22248499 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte drink (CHO-E; Lucozade Sport)
Number of subjects: 22
Study 22248499 — intervention group
Group type: COMPARATOR
Intervention: Flavor-matched placebo-electrolyte (PL)
Number of subjects: 22
Study 20363153 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (US)
Number of subjects: 83
Study 20363153 — intervention group
Group type: COMPARATOR
Intervention: Computed tomographic (CT) angiography
Number of subjects: 83
Study 19010143 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (n = 20)
Number of subjects: 40
Study 19010143 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) (n = 20)
Number of subjects: 40
Study 15707927 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial expression processing with gaze direction influence
Number of subjects: 0
Study 15707927 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted faces in expression judgments
Number of subjects: 0
Study 15707927 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze judgments influenced by expression
Number of subjects: 0
Study 15707927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity of expression processing to gaze direction
Number of subjects: 0
Study 15707927 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments of gaze direction
Number of subjects: 0
Study 12441015 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine, enalapril, hydrochlorothiazide, or both to control systolic blood pressure to <150 mmHg
Number of subjects: 2418
Study 12441015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 2418
Study 12441015 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine and lercanidipine
Number of subjects: 2418
Study 9934943 — intervention group
Group type: EXPERIMENTAL
Intervention: TPQ Novelty Seeking subscale score
Number of subjects: 170
Study 7587747 — intervention group
Group type: EXPERIMENTAL
Intervention: VCS-microsphere method
Number of subjects: 76
Study 7587747 — intervention group
Group type: EXPERIMENTAL
Intervention: VCS-microsphere method with CD3 gating
Number of subjects: 76
Study 2178396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily until complete ulcer healing (Group A)
Number of subjects: 81
Study 2178396 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg until complete relief of pain (Group B)
Number of subjects: 81
Study 2178396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily (Group A)
Number of subjects: 81
Study 2178396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine treatment (both groups)
Number of subjects: 81
Study 550419 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide (Amipaque; Winthrop)
Number of subjects: 150
Study 550419 — intervention group
Group type: COMPARATOR
Intervention: Dimer‐X
Number of subjects: 150
Study 550419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Number of subjects: 150
Study 31174502 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based skills-training program to improve skills to deal with performance anxiety
Number of subjects: 0
Study 31174502 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based skills-training program to improve social skills
Number of subjects: 0
Study 29936455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligomeric proanthocyanidin (OPC) 150 mg/day for 8 weeks
Number of subjects: 27
Study 29936455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 27344831 — intervention group
Group type: EXPERIMENTAL
Intervention: Point application treatment using herbal plaster on acupoints Dingchuan (EX-B1), Feishu (BL 13), Gaohuang (BL 43), and Danzhong (CV 17) for 2 to 4 hours on the first day of each of the three periods of the hot season.
Number of subjects: 135
Study 25260636 — intervention group
Group type: COMPARATOR
Intervention: Control (lactated Ringer's)
Number of subjects: 0
Study 25260636 — intervention group
Group type: EXPERIMENTAL
Intervention: nNOS inhibitor (5 mm N-propyl-l-arginine)
Number of subjects: 0
Study 25260636 — intervention group
Group type: EXPERIMENTAL
Intervention: eNOS inhibitor (10 mm N(5)-(1-iminoethyl)-l-ornithine dihydrochloride)
Number of subjects: 0
Study 25260636 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective NOS inhibitor (20 mm Nω-nitro-l-arginine methyl ester hydrochloride)
Number of subjects: 0
Study 22418272 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + access
Number of subjects: 96
Study 22418272 — intervention group
Group type: COMPARATOR
Intervention: Access-only
Number of subjects: 96
Study 22418272 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 19883910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐incision surgery (MIS)
Number of subjects: 56
Study 19883910 — intervention group
Group type: COMPARATOR
Intervention: Standard incision (STD)
Number of subjects: 56
Study 17629164 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg vaginal misoprostol
Number of subjects: 147
Study 17629164 — intervention group
Group type: COMPARATOR
Intervention: 25 microg vaginal misoprostol
Number of subjects: 147
Study 15894947 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (T) - 45 minutes cycling at intensity corresponding to anaerobic threshold, 4 to 5 times per week for 12 weeks
Number of subjects: 54
Study 15894947 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 54
Study 12540357 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit care
Number of subjects: 216
Study 12540357 — intervention group
Group type: COMPARATOR
Intervention: General medical wards care
Number of subjects: 216
Study 10589633 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm IVRA (0.4 mL/kg, max 25 mL)
Number of subjects: 14
Study 10589633 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVRA (0.6 mL/kg, max 45 mL)
Number of subjects: 14
Study 10589633 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVRA
Number of subjects: 14
Study 10589633 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm IVRA
Number of subjects: 14
Study 8727014 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder muscle fatigue
Number of subjects: 80
Study 8727014 — intervention group
Group type: COMPARATOR
Intervention: Active and passive repositioning tests
Number of subjects: 80
Study 8727014 — intervention group
Group type: COMPARATOR
Intervention: Arm dominance
Number of subjects: 80
Study 1927586 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of pseudoephedrine four times a day for 3 days
Number of subjects: 29
Study 1927586 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules four times a day for 3 days
Number of subjects: 29
Study 6349925 — intervention group
Group type: COMPARATOR
Intervention: Monophasic oral contraceptive Neovletta (30 micrograms ethinyl oestradiol + 150 micrograms levonorgestrel)
Number of subjects: 835
Study 6349925 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phasic oral contraceptive Trionetta (30/40/30 micrograms ethinyl oestradiol + 50/75/125 micrograms levonorgestrel)
Number of subjects: 835
Study 31674252 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolateral fixator
Number of subjects: 30
Study 31674252 — intervention group
Group type: COMPARATOR
Intervention: Circular frame
Number of subjects: 30
Study 27210034 — intervention group
Group type: EXPERIMENTAL
Intervention: Single implants placed in healed ridges
Number of subjects: 96
Study 27210034 — intervention group
Group type: COMPARATOR
Intervention: Single implants placed in extraction sockets
Number of subjects: 96
Study 26524414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidcombe Program (LP)
Number of subjects: 199
Study 26524414 — intervention group
Group type: COMPARATOR
Intervention: RESTART-DCM
Number of subjects: 199
Study 23422190 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa cotreatment during chemotherapy
Number of subjects: 16
Study 23422190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GnRHa)
Number of subjects: 16
Study 21157444 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (1200 mg/day for 8 weeks)
Number of subjects: 115
Study 21157444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 19136094 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 60
Study 19136094 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 60
Study 17143197 — intervention group
Group type: EXPERIMENTAL
Intervention: Resperate device-guided breathing exercises
Number of subjects: 30
Study 17143197 — intervention group
Group type: COMPARATOR
Intervention: Control group (listened to music, no therapeutic device)
Number of subjects: 30
Study 15383479 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low molecular weight heparin (LMWH) or IV unfractionated heparin (UFH) for short-term treatment of DVT.
Number of subjects: 0
Study 15383479 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants while awaiting diagnostic tests for patients with high clinical suspicion of DVT.
Number of subjects: 0
Study 15383479 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with LMWH or UFH for at least 5 days for acute DVT.
Number of subjects: 0
Study 15383479 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of vitamin K antagonist (VKA) together with LMWH or UFH on the first treatment day.
Number of subjects: 0
Study 15383479 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with VKA for 3 months for first episode of DVT secondary to a transient risk factor.
Number of subjects: 0
Study 15383479 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with VKA for at least 6 to 12 months for first episode of idiopathic DVT.
Number of subjects: 0
Study 15383479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose of VKA adjusted to maintain a target INR of 2.5 (range 2.0 to 3.0).
Number of subjects: 0
Study 15383479 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of elastic compression stocking for prevention of postthrombotic syndrome.
Number of subjects: 0
Study 15383479 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute treatment with SC LMWH or IV UFH for objectively confirmed nonmassive PE.
Number of subjects: 0
Study 15383479 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation against systemic thrombolytic therapy for most patients with PE.
Number of subjects: 0
Study 11244515 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol after coronary atherectomy
Number of subjects: 0
Study 11244515 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel atherectomy device in the Pullback Atherectomy (PAC) pilot trial
Number of subjects: 0
Study 8866633 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg quinine
Number of subjects: 7
Study 8866633 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg quinine
Number of subjects: 7
Study 8866633 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg quinine
Number of subjects: 7
Study 8866633 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses (250, 500, 1000 mg)
Number of subjects: 7
Study 1948128 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interferon-alfa-2b at a dose of 5 x 10(6) IU subcutaneously three times per week
Number of subjects: 120
Study 1948128 — intervention group
Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 120
Study 1948128 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interferon-alfa-2b
Number of subjects: 120
Study 6503213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate buffer during hemodialysis, hemofiltration, and hemodiafiltration
Number of subjects: 5
Study 6503213 — intervention group
Group type: COMPARATOR
Intervention: Acetate buffer during hemodialysis
Number of subjects: 5
Study 6503213 — intervention group
Group type: COMPARATOR
Intervention: Acetate buffer during hemofiltration
Number of subjects: 5
Study 31527240 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive, nonenforcement contact with uniformed police officers
Number of subjects: 0
Study 31527240 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29334906 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg)
Number of subjects: 6042
Study 29334906 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (1-4 mg)
Number of subjects: 6042
Study 26725476 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-RFCBT
Number of subjects: 251
Study 26725476 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided internet-RFCBT
Number of subjects: 251
Study 26725476 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 251
Study 22144347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 56
Study 22144347 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 56
Study 22144347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (post-MBSR)
Number of subjects: 56
Study 20058261 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-stiffness shoe
Number of subjects: 60
Study 20058261 — intervention group
Group type: COMPARATOR
Intervention: Constant-stiffness control shoe
Number of subjects: 60
Study 18833113 — intervention group
Group type: EXPERIMENTAL
Intervention: Xydifonum administered via various modes (electrophoretic, peroral, ointment) with heparin and photopheresis using photomatrix LED equipment.
Number of subjects: 80
Study 18833113 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-operated patients) receiving standard treatment without xydifonum.
Number of subjects: 80
Study 16422309 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically implanted left ventricular assist device
Number of subjects: 0
Study 16422309 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 14601013 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for hyperactivity
Number of subjects: 0
Study 14601013 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence level assignment method
Number of subjects: 0
Study 14601013 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrap method for confidence levels
Number of subjects: 0
Study 10565503 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 40
Study 10565503 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 40
Study 8877012 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily for 1 year)
Number of subjects: 1716